The case Boehringer Ingelheim (Canada) Ltd. v. Sandoz Canada Inc. involves Boehringer Ingelheim (BI) and the defendants, Sandoz and Sun Pharma. The dispute is about patent infringement concerning orally administered empagliflozin tablets, which are alleged to infringe several BI patents. Here’s a brief summary of the key points:

• Protective Orders: Both parties agreed on protective orders to manage confidentiality and information sharing. BI marked certain documents as "Solicitors’ Eyes Only" (SEO), restricting access to external legal counsel only.

• Redactions:

  • BI made redactions based on relevance and compliance with European privacy regulations (GDPR). Information such as personal data, names of individuals involved in experiments but not named as inventors, and contact details were redacted.
  • The court evaluated the appropriateness of these redactions based on the "clearly irrelevant" standard.
  • Redactions were considered appropriate for non-inventor names and irrelevant test results related to compounds not directly involved in the patents at issue.

• SEO Designations:

  • BI marked internal documents relating to research and development as SEO due to their sensitive and confidential nature.
  • The court found that BI had demonstrated the SEO designation was applied in good faith, aligning with the criteria set in the protective orders.

• Court's Decision:

  • The court dismissed the defendants’ challenges to the redactions and SEO designations. BI's motion to uphold these designations was granted.
  • Costs were reserved, and parties were encouraged to agree on the cost award by December 11, 2023.